Accelerating antibody research requires access to high-quality antibodies and proteins, efficient production timelines, and reliable partnerships. Biointron, a leading Contract Research Organization (CRO) specializing in antibody discovery, expression, and optimization, has become the preferred choi

Approved in 1998, trastuzumab (commonly known as Herceptin) marked a transformative milestone in oncology. Designed to target the human epidermal growth factor receptor 2 (HER2), trastuzumab provided a breakthrough for patients with HER2-positive breast cancer.

The development of custom antibodies is a critical component in advancing research and therapeutic innovation. Biointron, a Contract Research Organization (CRO) specializing in antibody expression services, provides comprehensive support to biotech companies seeking reliable, scalable, and high-quality solutions for their antibody production needs.

Biological reagents, particularly unreliable antibodies, can significantly hinder scientific progress. High-quality antibodies are essential for obtaining consistent and biologically accurate results.

In vivo antibody testing is required to evaluate the therapeutic potential of monoclonal antibodies (mAbs) and other biologics. Unlike in vitro models, which primarily offer insights into molecular interactions, in vivo studies provide essential data on an antibody's pharmacodynamics, pharmacokinetics, and overall safety profile within the complexity of living organisms.

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with potent cytotoxic payloads. This strategy allows for selective delivery of toxic agents to tumor cells while minimizing harm to healthy tissues.

Copyright © 2023 Nudelman/ShutterstockRituximab was first approved by the FDA in 1997 for the treatment of CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). Its approval marked a significant milestone in oncology and paved the way for the development of antibody-based therapies. By targeting the

Discover Infliximab, the first monoclonal antibody for inflammatory diseases. Explore our catalog of antibody products for in vivo research today.

Abinvivo offers a range of antibody products for in vivo research, each designed to meet specific research needs and applications in preclinical studies and antibody development.

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with the potent cytotoxic effects of chemotherapeutic agents. The development of ADCs traces back over a century and mirrors advancements in molecular biology and biotechnology, resulting in several approved drugs used in oncology today.

Antibody-drug conjugates (ADCs) represent a promising approach in oncology due to their ability to deliver cytotoxic drugs selectively to cancer cells. By combining the tumor-targeting specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic agents, ADCs are engineered to improve therapeutic outcomes while minimizing damage to healthy tissue. However, their therapeutic efficacy is not only dependent on the specific antibody or drug payload but also on a critical parameter known as the drug–antibody ratio (DAR).

DOI:10.1016/j.trecan.2024.07.002Bispecific antibodies (bsAbs) are a class of engineered therapeutic molecules designed to engage two different epitopes or antigens simultaneously, providing them with unique functionalities that go beyond traditional monoclonal antibodies. By targeting two distinct a

Discover Biointron's anti-mouse antibodies for studying immune pathways in murine models. Explore PD-1, PD-L1, & CTLA-4 antibodies for cancer, immunology, & autoimmune research.

Learn how isotype negative antibodies & controls enhance specificity in experiments, validating antibody-antigen interactions & supporting Fc-engineered antibody design.

Explore Benchmark Positive Antibodies and their role in in vivo research. Learn how anti-human antibodies targeting PD-1, CTLA-4, HER2, and 4-1BB drive drug development.